Filing Flows › Nuo Therapeutics (AURX) › Q2 2026
Nuo Therapeutics (AURX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Nuo Therapeutics (AURX) reported revenue of $1.8M for the second quarter 2026 (Q2 2026), +153% from a year earlier and +36% from the quarter before. Operating margin was -9.4%, net loss $278K (15.7% of revenue).
Nuo Therapeutics, Q2 2026: revenue $1.8M (+153% year over year), operating margin -9.4%, net loss $278K, operating cash flow −$236K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.8M | +36% | +153% |
| Operating profit | −$167K | — | — |
| Net earnings | −$278K | — | — |
| Operating cash flow | −$236K | — | -190% |
What changed
Revenue was $1.8M in Q2 2026, up 153% year over year and up 36% from the previous quarter. Aurix and Private Label Kits was the largest line at 92% of revenue. License added $3K year over year (up 4%), 0% of the total change.
Gross margin was 66.1%, down 11.1 points from Q2 2025. Operating costs exceeded revenue by $167K, an operating margin of -9.4%. Operating expenses grew 12% against revenue growth of 153%. The quarter ended with a net loss of $278K, narrower than the previous quarter's $618K loss.
Operating cash flow was −$236K. Non-cash charges added back $26K of depreciation and $41K of share-based compensation. Working capital and other items used $27K. Capital expenditures of $253K exceeded it, leaving free cash flow of −$490K.
Questions
What was Nuo Therapeutics' revenue in the second quarter 2026?
Nuo Therapeutics (AURX) reported revenue of $1.8M for the second quarter 2026 (Q2 2026), +153% from a year earlier and +36% from the quarter before.
Was Nuo Therapeutics profitable in the second quarter 2026?
Operating loss was $167K (-9.4% of revenue) and net loss $278K.
Source: Nuo Therapeutics 10-Q on SEC EDGAR.